Centene Corp.
CNC
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $32.2B
$67.35
▲ +3.25%
P/E
-6.46
Mkt Cap
$32.2B
52-Wk Range
$28.24–$69.36
52-Week Range
$28.24 - $69.36
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 120.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive Government Program Expertise
- Diversified Healthcare Service Portfolio
- Strong Geographic Market Presence
- Cost-Efficient Healthcare Delivery Model
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Expanding Medicaid Enrollment
Value
Attractively priced below Managed Care & Health Insurance peer average
Momentum
Strong
+8.7% over 3m
Quality
Thin
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CNC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $2.51 vs $1.09 consensus (+130.3% surprise). Revenue of $53.6B vs $47.6B expected (+12.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+130.3%
Revenue trend · last 8Q
—
+3%
+15%
+22%
+18%
+22%
+7%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$42.0B
$40.8B
$46.6B
$48.7B
$49.7B
$49.7B
$49.9B
$53.6B
Margins · last 8Q
Gross
25.8%
Operating
2.2%
Profit
2.0%
Wall Street consensus
17 analysts · 53% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
53%
Hold
41%
Sell
6%
Median Price Target
—
Latest: Bernstein · Aug 3, 2026
vs Industry
How CNC stacks vs Medical - Healthcare Plans
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related